Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | NQO2 | P16083 | 3/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | GAPDH | P04406 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16436206 | 1.00 | ELANE (0.36) | ELANEKMT2ATHRBATMNQO2 | |
| SCHEMBL16436233 | 0.93 | ELANE (0.41) | ELANEKMT2AATMNQO2STS | |
| SCHEMBL16436198 | 0.91 | THRB (0.38) | THRBNQO2STSGAPDHMAOB | |
| SCHEMBL16436316 | 0.90 | THRB (0.37) | THRBNQO2STSGAPDHMAOB | |
| SCHEMBL16436356 | 0.88 | PTGS2 (0.31) | STSMAOBPTGS2 | |
| SCHEMBL16436243 | 0.88 | ELANE (0.37) | ELANEKMT2ATHRBATMNQO2 | |
| SCHEMBL16436241 | 0.88 | ELANE (0.37) | ELANEKMT2ATHRBATMNQO2 | |
| SCHEMBL16436272 | 0.88 | ELANE (0.40) | ELANEKMT2AATMNQO2STS | |
| SCHEMBL18194819 | 0.87 | ELANE (0.42) | ELANEKMT2ATHRBATMGAPDH | |
| SCHEMBL18194796 | 0.87 | ELANE (0.42) | ELANEKMT2ATHRBATMGAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315603-B2 | Polymerizable compound having oxygen-containing five-membered ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-04-19 | — | — | US | disclosed |
| US-9315603-B2 | Polymerizable compound having oxygen-containing five-membered ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20150034871-A1 | POLYMERIZABLE COMPOUND HAVING OXYGEN-CONTAINING FIVE-MEMBERED RING, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-02-05 | — | — | US | disclosed |
| US-20150034871-A1 | POLYMERIZABLE COMPOUND HAVING OXYGEN-CONTAINING FIVE-MEMBERED RING, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150034871-A1 | POLYMERIZABLE COMPOUND HAVING OXYGEN-CONTAINING FIVE-MEMBERED RING, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD1, OCIAD2, SCO2 | ELANE 2946/4885KMT2A 3863/4885THRB 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.